ClinicalTrials.gg
TerminatedNCT03348904Updated Jun 13, 2019Results posted

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

A Phase 3 interventional study of Nivolumab and Epacadostat in Lung Cancer, sponsored by Incyte Corporation. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-13.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Why this study was terminated
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
111th of 120
2 · median 66
Started
2017
with 23 others
Phase 3
24 of 120
3 open now
Registered
55th of 120
by date

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 111th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 55th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Non-small cell lung cancer
  • programmed cell death protein 1 (PD-1) antibody
  • indoleamine 2,3-dioxygenase (IDO) inhibitor
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

This study's enrollment of 2 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed stage IV or recurrent NSCLC of squamous or non-squamous histology that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  • No prior treatment with systemic anti-cancer therapy for Stage IV disease.
  • (ECOG) Performance Status of 0 to1.
  • by computed tomography or magnetic resonance imaging per v1.1.
  • Documentation of program death ligand-1 () status of 0 to 49% by IHC performed by the central laboratory prior to randomization.
  • Other protocol inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Known epidermal growth factor receptor (EGFR) mutations sensitive to available targeted inhibitor therapy.
  • Known ALK or ROS1 rearrangements sensitive to available targeted inhibitor therapy.
  • Untreated central nervous system (CNS) .
  • Unevaluable status or PD-L1 status of ≥ 50% by IHC performed by a central laboratory.
  • Carcinomatous meningitis.
  • Active, known or suspected disease.
  • Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, IDO1 targeted agent, or any other antibody or drug targeting T cell co-stimulation or checkpoint pathways.
  • History of allergy or to platinum-containing compounds or study drug components.
  • Physical and laboratory test findings outside the protocol-defined range.
  • Other protocol exclusion criteria may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Arm A

    Nivolumab plus epacadostat in combination with platinum doublet

    Drug: Nivolumab · Drug: Epacadostat · Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pemetrexed

  • Active comparator
    Arm B

    Platinum doublet chemotherapy

    Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pemetrexed

  • Experimental
    Arm C

    Nivolumab plus placebo in combination with platinum doublet chemotherapy.

    Drug: Nivolumab · Drug: Placebo · Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pemetrexed

Interventions

  • Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.

    Also known as: BMS-936558

  • Epacadostat administered orally at the protocol-defined dose twice daily.

    Also known as: INCB024360

  • DrugPlacebo

    Matching placebo for epacadostat administered orally twice daily.

  • Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

    Defined as the time from randomization to the date of death from any cause.

    Time frame: Approximately 38 months

  2. Progression-free Survival (PFS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

    Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review, or death due to any cause, whichever occurs first.

    Time frame: Approximately 25 months

Secondary outcomes

  1. Objective Response Rate (ORR) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

    Defined as the proportion of participants who achieve a confirmed best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by blinded independent central review.

    Time frame: Approximately 25 months

  2. Duration of Response (DOR) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

    Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Approximately 25 months

  3. Estimate of OS of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

    Defined as the time from randomization to the date of death from any cause.

    Time frame: Approximately 38 months

  4. Estimate of PFS of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

    Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Approximately 25 months

  5. Estimate of ORR of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

    Defined as the proportion of participants who achieve a confirmed best response of CR or PR per RECIST v1.1 criteria as assessed by blinded independent central review.

    Time frame: Approximately 25 months

  6. Estimate of DOR of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

    Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Approximately 25 months

08

Results

Posted Jun 13, 2019

Participant flow

Approximately 630 participants were planned to be randomized. Prior to the termination of the study, 2 participants were randomized to the Platinum Doublet Chemotherapy arm (Arm B) and treated.

Participant flow — Overall Study
MilestoneNivolumab + Epacadostat/Platinum Doublet ChemotherapyPlatinum Doublet ChemotherapyNivolumab + Placebo Combination/Platinum Doublet Chemotherapy
Started020
Completed010
Not completed010
Withdrew: Administrative reason by the sponsor010

Outcome measures

PrimaryOverall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

Defined as the time from randomization to the date of death from any cause.

Time frame:
Approximately 38 months

No measurements were reported for this outcome.

PrimaryProgression-free Survival (PFS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review, or death due to any cause, whichever occurs first.

Time frame:
Approximately 25 months

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

Defined as the proportion of participants who achieve a confirmed best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by blinded independent central review.

Time frame:
Approximately 25 months

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)

Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.

Time frame:
Approximately 25 months

No measurements were reported for this outcome.

SecondaryEstimate of OS of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

Defined as the time from randomization to the date of death from any cause.

Time frame:
Approximately 38 months

No measurements were reported for this outcome.

SecondaryEstimate of PFS of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review or death due to any cause, whichever occurs first.

Time frame:
Approximately 25 months

No measurements were reported for this outcome.

SecondaryEstimate of ORR of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

Defined as the proportion of participants who achieve a confirmed best response of CR or PR per RECIST v1.1 criteria as assessed by blinded independent central review.

Time frame:
Approximately 25 months

No measurements were reported for this outcome.

SecondaryEstimate of DOR of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)

Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.

Time frame:
Approximately 25 months

No measurements were reported for this outcome.

Adverse events

Collected over From the initiation of study treatment until 30 days after last dose of study treatment or up to study termination date 22May2018.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Epacadostat/Platinum Doublet Chemotherapy———
Platinum Doublet Chemotherapy1/2 (50%)1/2 (50%)2/2 (100%)
Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy———
Most frequent serious events
Most frequent serious events
EventNivolumab + Epacadostat/Platinum Doublet ChemotherapyPlatinum Doublet ChemotherapyNivolumab + Placebo Combination/Platinum Doublet Chemotherapy
DehydrationMetabolism and nutrition disorders—1/2—
Back painMusculoskeletal and connective tissue disorders—1/2—
OsteomyelitisMusculoskeletal and connective tissue disorders—1/2—
Most frequent other events
Showing 10 of 13
Most frequent other events
EventNivolumab + Epacadostat/Platinum Doublet ChemotherapyPlatinum Doublet ChemotherapyNivolumab + Placebo Combination/Platinum Doublet Chemotherapy
ConstipationGastrointestinal disorders—2/2—
DyspnoeaRespiratory, thoracic and mediastinal disorders—1/2—
Flank painMusculoskeletal and connective tissue disorders—1/2—
NauseaGastrointestinal disorders—1/2—
VomitingGastrointestinal disorders—1/2—
Weight decreasedInvestigations—1/2—
AnaemiaBlood and lymphatic system disorders—1/2—
HypotensionVascular disorders—1/2—
PyrexiaGeneral disorders—1/2—
ThrombocytopeniaBlood and lymphatic system disorders—1/2—

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Nivolumab + Epacadostat/Platinum Doublet ChemotherapyPlatinum Doublet ChemotherapyNivolumab + Placebo Combination/Platinum Doublet ChemotherapyTotal
<=18 years0000
Between 18 and 65 years0202
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Epacadostat/Platinum Doublet ChemotherapyPlatinum Doublet ChemotherapyNivolumab + Placebo Combination/Platinum Doublet ChemotherapyTotal
Female0000
Male0202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nivolumab + Epacadostat/Platinum Doublet ChemotherapyPlatinum Doublet ChemotherapyNivolumab + Placebo Combination/Platinum Doublet ChemotherapyTotal
White or Caucasian0202
09

Study locations

2 sites
  • Pacific Cancer Medical Center, Inc
    Anaheim, California 92801, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2018, 4 months.

Results were first posted in Jun 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2017
First posted
Nov 21, 2017
StartActual
Dec 27, 2017
Primary completionActual
May 22, 2018
CompletionActual
May 22, 2018
Results first posted
Jun 13, 2019
Last update
Jun 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03348904
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 21, 2017
Start date
Dec 27, 2017
Primary completion
May 22, 2018
Completion
May 22, 2018
Results posted
Jun 13, 2019
Last update
Jun 13, 2019

Study contacts

Sridhar K. Rabindran, PhD
study director · Bristol-Myers Squibb Research and Development

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Epacadostat

Start the discussion